Methylene Blue Explained: What the Studies Show

What methylene blue is (context + mainstream use)

• Originally a fabric dye (1876), later found to have medical effects.
• It stains blue (including the mouth and urine, and it can stain surfaces), which is why it’s known as a dye.
• Mainstream clinical medicine recognizes it as a medicine.
• Historically used for malaria and still approved for certain blood disorders (for emergency/medical use).

How it’s said to work (simplified mechanism)

Methylene blue is described as acting as an alternative electron carrier in the mitochondrial electron transport chain.

• If one step is rate-limiting/sluggish, it may help bypass the slow step to keep energy production running.
• Research mentioned includes:
  • Low-dose effects on mitochondrial function
  • Increased cytochrome oxidase activity and changes in cerebral metabolic rate (framed in a memory/neurop protection context)

Key takeaway: dose changes the effects

The video emphasizes that methylene blue is dose-dependent.

• At certain higher dose thresholds, it may produce opposite effects.
• A discrepancy is noted between:
  • Consumer supplement doses
  • Medical/hospital dosing and study dosing
• The presenter suggests this may meaningfully affect how results are interpreted.

Dosage information discussed (as reported in studies/clinical protocols)

Not advice—presented as “what the research says” in the subtitles.

Approved medical use (IV blood disorder)

• 1–2 mg/kg IV over 3–5 minutes
• Possible repeat dosing of 1 mg/kg if levels drop within 30–60 minutes
• A ceiling kept under 7 mg/kg due to risk of adverse/opposite effects

Human cognition/memory study (single oral dose)

• Around 280 mg (about 4 mg/kg for a 70 kg adult)
• Randomized study with brain imaging (fMRI, n=26)
• Reported ~7% memory improvement (not broadly replicated, per the discussion)

Other medical protocols mentioned

• Malaria (with other antimalarials): 10 mg/kg twice daily for 3 days (IV)
• Septic shock: IV protocols
• Mood/Alzheimer’s: small trials and a large phase 3 Alzheimer’s trial that missed its primary endpoint

Animal study finding (dose-response pattern)

• Memory improved in a low dose range (reported peak around 4 mg/kg)
• At higher doses (e.g., 5 mg/kg), benefits disappeared
• At much higher doses (50–100 mg/kg), it could cause memory impairment

Wellness/productivity/product-performance claims (graded by evidence)

The presenter uses a grading system for claim strength:

• A: Proven in people
• B: Limited human data
• C: Animal/lab only
• D: Mechanism suggests it should work

Example gradings discussed

A / B (stronger evidence)

• Treats the blood disorder (FDA-approved) — A
• Antimalarial use — B
• Memory/cognition, mood/depression, neurop protection, septic shock — mostly B or C depending on the category

C (mostly animal/lab evidence)

• Anti-inflammatory, antimicrobial, antiviral
• Skin/photoaging, longevity (inferred from animal similarity + mechanisms)

D (mechanism-based, not firmly proven in humans)

• Antioxidant effects
• Energy/fatigue improvement (plausible via mitochondria/electron transport)

E / anecdotal level

• Exercise performance (despite the energy mechanism, not many dramatic reports)

Self-care / practical strategies implied by the video

• Evidence-aware approach to dosing
  • Use the idea that low dose may act differently than high dose
  • Wait for more human dose-response and longer trials before assuming outcomes
• Personal experimentation—but with caution
  • The presenter frames the video as reflecting research + personal experience, not a universal prescription
• Stacking/multi-target approach
  • Argues single-drug isolation trials may miss benefits of multi-pathway (“multiway”) approaches
  • Suggests methylene blue could work best in combination (synergy/mitigation), though not presented as proven

Biggest safety concern highlighted (important)

Risk with serotonergic medications/drugs

• Methylene blue is described as an MAOI (monoamine oxidase inhibitor).
• Combining it with SSRIs/SNRIs or other serotonin-increasing/recreational drugs may trigger serotonin syndrome.
• Symptoms described as severe “serotonin syndrome” sensations (e.g., intense anxiety-like experience and physical distress).

Presenter’s personal safety stance

• Kept doses lower to reduce risk.
• Highly cautious about combinations affecting serotonin.

What users most commonly report (anecdotes)

Most common benefits mentioned

• Energy
• Brain fog reduction
• Focus
• Mood

Less desirable/negative anecdotal report mentioned

• Anhedonia (feeling emotionless / loss of pleasure)
  • The presenter says causality is unclear.

Key limitation of anecdotal evidence emphasized

• Unclear dosing and stacking
• People may not know what else they’re combining
• Effects could be driven by the combination rather than methylene blue alone

Presenter’s personal experience (self-care narrative)

• Used methylene blue for about a decade
• Initially interested due to anti-aging/skin interests
• Motivated by a collaborator/mentor (Coach Trevor) who recommended it enthusiastically for biohacking experiments
• Uses described:
  • Morning use to pair with other compounds (presenter says it helps extend half-life)
  • Night use for relaxation/calm effects
  • A past “mega dose” during a viral illness (described as helping recovery quickly)
• Ongoing intention:
  • Avoid situations that might increase serotonin too much due to MAOI/serotonin syndrome risk

Sources / presenters mentioned

• Presenter: Coach Trevor and “I” (main speaker; name not provided in subtitles)
• Other referenced source: “this progress in neurobiology” / a neurobiology study (not specifically named in subtitles)
• No specific named journals/authors/organizations are provided in the subtitles excerpt.